Invivyd (NASDAQ:IVVD) Insider Sells $16,095.60 in Stock

Posted by Brenda Bartman on Aug 21st, 2026

Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) insider Timothy Edward Lee sold 22,355 shares of Invivyd stock in a transaction on Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $16,095.60. Following the sale, the insider directly owned 197,362 shares of the company’s stock, valued at approximately $142,100.64. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Timothy Edward Lee also recently made the following trade(s):

On Tuesday, August 18th, Timothy Edward Lee sold 18,425 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total value of $15,477.00.

Invivyd Price Performance

Invivyd stock opened at $0.95 on Friday. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The stock has a market cap of $280.26 million, a PE ratio of -2.88 and a beta of 0.71. The stock’s fifty day moving average is $0.78 and its two-hundred day moving average is $1.22.

Invivyd (NASDAQ:IVVD – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The business had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. On average, research analysts expect that Invivyd, Inc. will post -0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. HC Wainwright restated a “buy” rating on shares of Invivyd in a research report on Tuesday. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $8.00.

Read Our Latest Report on IVVD

Institutional Trading of Invivyd

A number of large investors have recently made changes to their positions in the company. Eventide Asset Management LLC purchased a new position in Invivyd during the 4th quarter worth approximately $14,349,000. Perceptive Advisors LLC acquired a new position in Invivyd during the fourth quarter worth approximately $53,809,000. BVF Inc. IL purchased a new stake in Invivyd in the fourth quarter valued at approximately $48,227,000. UBS Group AG lifted its stake in Invivyd by 683.8% in the fourth quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock valued at $2,596,000 after buying an additional 916,842 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Invivyd in the second quarter valued at approximately $578,000. 70.36% of the stock is owned by institutional investors and hedge funds.

Invivyd Company Profile

(Get Free Report)

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.